(3aR)-1,3a,8-Trimethyl-1 ,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.
1. A method of treating Parkinson's disease and Lewy bodies disease disease in humans, comprising administering to a population of human patients suffering from Parkinson's disease or Lewy bodies disease a pharmaceutical composition consisting of from about 1 mg to about 30 mg of posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once-a-day basis, such that (i) the treatment provides (i) disease modification; (ii) symptomatic improvement; or (iii) both (i) and (ii).
2. The method of claim 1 , wherein said administration of posiphen provides peak circulating levels of posiphen in said human subject, and the peak plasma circulating level ranges from about 10 ng/mL to about 160 ng/ml in said human subject.
3. The method of claim 1 , wherein said administration of posiphen provides peak circulating levels of posiphen in said human subject, and the peak plasma circulating level is reached within about 3 hours after said administration.
4. The method of claim 1 , wherein said administration results in the plasma circulating level of posiphen is equal to or greater than about 20 ng/mL for at least 9 hours after said administering.
5. The method of claim 1 , wherein said administering results in a brain level of posiphen that ranges from about 4 to about 10 times the plasma level of posiphen in said subject.
6. The method of claim 1 , wherein the half-life of posiphen in plasma after administering is about 5 hours, the half-life of posiphen in cerebrospinal fluid after administering is about 12 hours, and the brain level of posiphen ranges from about 4 to about 10 times the plasma level of posiphen in said subject.
7. The method of claim 1 , wherein the pharmaceutical composition includes from about 7.5 mg to about 30 mg of posiphen or a pharmaceutically acceptable salt thereof.
8. The method of claim 1 , wherein the production of alpha-synuclein (SNCA) in human patients is inhibited.
9. The method of claim 1 , wherein said pharmaceutical composition is orally administered.
10. The method of claim 1 , wherein said pharmaceutical composition is parenterally administered.
11. A method of treating Parkinson's disease and Lewy bodies disease in humans, comprising administering a pharmaceutical composition consisting of from about 7.5 mg to about 30 mg of posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients on a once-a-day basis to a population of human patients suffering from Parkinson's disease or Lewy bodies disease, such that the treatment provides (i) disease modification; (ii) symptomatic improvement; or (iii) both (i) and (ii).
12. The method of claim 11 , wherein said pharmaceutical composition is orally administered.
13. The method of claim 11 , wherein said pharmaceutical composition is parenterally administered.
14. The method of claim 1 , wherein said pharmaceutical composition is administered intravenously.
15. The method of claim 11 , wherein the treatment inhibits production of neurotoxic aggregating protein selected from the group consisting of alpha-synuclein (SNCA) in the human patients.
16. A method of providing disease modification in Parkinson's and Lewy bodies disease disease, comprising administering to a population of human patients suffering from Parkinson's disease or Lewy bodies disease a pharmaceutical composition consisting of from about 4 mg to about 20 mg of posiphen or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable excipients, on a once-a-day basis, such that the treatment provides (i) disease modification; (ii) symptomatic improvement; or (iii) both (i) and (ii).
17. The method of claim 16 , wherein the treatment inhibits production of alpha-synuclein (SNCA)-in the human patients.
18. The method of claim 17 , wherein said pharmaceutical composition is orally administered.
19. The method of claim 17 , wherein said pharmaceutical composition is parenterally administered.